DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
(European Association for the Study of the Liver) Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news
More News: Cirrhosis | Health | Hepatitis | Hepatitis C | International Medicine & Public Health | Liver | Liver Transplant | Politics | Study | Transplant Surgery | Transplants | Urology & Nephrology